AI Article Synopsis
- Researchers developed cationic nanoliposomes loaded with garcinol (GAR) to enhance its antitumor effects on B16F10 melanoma cells, using two types of phospholipids, DSPC and DPPC, for comparison.
- Various assays and imaging techniques showed that GAR-DPPC formulations had better cellular uptake, cytotoxicity, and tumor inhibition compared to GAR-DSPC and free GAR.
- Findings suggest that cationic nanoliposomal formulations like GAR-DPPC could offer a promising new approach for treating skin cancer.
Article Abstract
Garcinol (GAR)-loaded cationic nanoliposomes were developed to achieve potential antitumor efficacy on B16F10 melanoma cells and . Two different phospholipids namely, distearoyl phosphatidylcholine (DSPC) and dipalmitoyl phosphatidylcholine (DPPC) were used in formulation to elucidate the difference in cellular uptake, cytotoxicity, tumor uptake (by scintigraphic imaging after technetium-99m radiolabeling) and therapeutic efficacy. Different protocols, for example, MTT assay, apoptosis study, gene expression analysis, chromatin condensation and cytoskeleton breakdown analysis in B16F10 cell lines as well as scintigraphic analysis and tumor inhibition studies (B16F10 tumor xenograft model) revealed superiority of GAR-DPPC than GAR-DSPC and free GAR in melanoma prevention. Cationic nanoliposomal formulations could be a future medication for skin cancer treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/nnm-2019-0022 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!